BRPI0921469A2 - proteínas de ligação que inibem a interação com o receptor de vegf-a - Google Patents

proteínas de ligação que inibem a interação com o receptor de vegf-a

Info

Publication number
BRPI0921469A2
BRPI0921469A2 BRPI0921469A BRPI0921469A BRPI0921469A2 BR PI0921469 A2 BRPI0921469 A2 BR PI0921469A2 BR PI0921469 A BRPI0921469 A BR PI0921469A BR PI0921469 A BRPI0921469 A BR PI0921469A BR PI0921469 A2 BRPI0921469 A2 BR PI0921469A2
Authority
BR
Brazil
Prior art keywords
vegf
receptor
binding proteins
inhibit interaction
inhibit
Prior art date
Application number
BRPI0921469A
Other languages
English (en)
Inventor
Hans Kaspar Binz
Michael Tobias Stumpp
Patrik Forrer
Original Assignee
Molecular Partners Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Molecular Partners Ag filed Critical Molecular Partners Ag
Publication of BRPI0921469A2 publication Critical patent/BRPI0921469A2/pt
Publication of BRPI0921469B1 publication Critical patent/BRPI0921469B1/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702Regulators; Modulating activity
    • C07K14/4703Inhibitors; Suppressors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • C07K14/515Angiogenesic factors; Angiogenin
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0921469-0A 2008-11-03 2009-11-03 Proteínas de ligação que inibem a interação com o receptor de vegf-a, composição farmacêutica BRPI0921469B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08168166.0 2008-11-03
EP08168166 2008-11-03
PCT/EP2009/064483 WO2010060748A1 (en) 2008-11-03 2009-11-03 Binding proteins inhibiting the vegf-a receptor interaction

Publications (2)

Publication Number Publication Date
BRPI0921469A2 true BRPI0921469A2 (pt) 2016-01-12
BRPI0921469B1 BRPI0921469B1 (pt) 2022-01-18

Family

ID=40149742

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0921469-0A BRPI0921469B1 (pt) 2008-11-03 2009-11-03 Proteínas de ligação que inibem a interação com o receptor de vegf-a, composição farmacêutica

Country Status (15)

Country Link
US (2) US8901076B2 (pt)
EP (2) EP2358746B1 (pt)
JP (2) JP5954990B2 (pt)
KR (1) KR101698362B1 (pt)
CN (2) CN107011425B (pt)
AU (1) AU2009319204B2 (pt)
BR (1) BRPI0921469B1 (pt)
CA (1) CA2742241C (pt)
DK (1) DK2358746T3 (pt)
ES (1) ES2836948T3 (pt)
IL (1) IL212589A (pt)
MX (2) MX359570B (pt)
NZ (1) NZ592591A (pt)
RU (2) RU2650765C1 (pt)
WO (1) WO2010060748A1 (pt)

Families Citing this family (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4976412B2 (ja) 2005-12-01 2012-07-18 ベー・エル・アー・ハー・エム・エス・ゲーエムベーハー エンドセリン、エンドセリンアゴニスト及びアドレノメジュリンアンタゴニストによる危篤患者の診断及び治療のための方法
KR101482483B1 (ko) 2006-04-07 2015-01-15 에르피오 세러퓨틱스 인코포레이티드 인간 단백질 타이로신 포스파타아제 베타(hptp베타)에 결합하는 항체 및 그의 용도
AU2014243418B2 (en) * 2010-04-30 2016-09-22 Molecular Partners Ag Modified binding proteins inhibiting the VEGF-A receptor interaction
AR081361A1 (es) 2010-04-30 2012-08-29 Molecular Partners Ag Proteinas de union modificadas que inhiben la interaccion de receptor del factor de crecimiento endotelial vascular de glicoproteina a vegf-a
CN113278077A (zh) * 2010-11-26 2021-08-20 分子组合公司 设计的与血清白蛋白结合的重复蛋白
JP2014519808A (ja) 2011-04-29 2014-08-21 ヤンセン バイオテツク,インコーポレーテツド Il4/il13に結合する反復タンパク質及び使用
WO2012172054A1 (en) 2011-06-16 2012-12-20 Scil Proteins Gmbh Modified multimeric ubiquitin proteins binding vegf-a
PT2780371T (pt) 2011-11-16 2019-01-30 Adrenomed Ag Anticorpo anti-adrenomedulina (adm) ou fragmento de anticorpo anti-adm ou uma estrutura não ig anti-adm para a regulação do equilíbrio de fluidos num doente com uma doença aguda ou crónica
AU2012338731B2 (en) 2011-11-16 2017-07-06 Adrenomed Ag Anti-adrenomedullin (ADM) antibody or anti-ADM antibody fragment or anti-ADM non-Ig scaffold for prevention or reduction of organ dysfunction or organ failure in a patient having a chronic or acute disease or acute condition
PT2594587E (pt) 2011-11-16 2014-08-27 Adrenomed Ag Anticorpo anti-adrenomedulina (adm) ou fragmento de anticorpo anti-adm ou andaime proteico não ig anti-adm para diminuir o risco de mortalidade num paciente com uma doença aguda ou crónica ou num estado agudo
CN118105479A (zh) 2011-11-16 2024-05-31 艾德里诺医药公司 用于治疗的抗肾上腺髓质素(ADM)抗体或抗ADM抗体片段或抗ADM非Ig骨架
US9535060B2 (en) 2011-11-16 2017-01-03 Sphingotec Gmbh Adrenomedullin assays and methods for determining mature adrenomedullin
CA2856142A1 (en) 2011-11-16 2013-05-23 Adrenomed Ag Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy of an acute disease or acute condition of a patient for stabilizing the circulation
CN103308670B (zh) 2012-03-08 2017-06-09 思芬构技术有限公司 用于预测对象患糖尿病和/或代谢综合征的风险的方法
CN103308689B (zh) 2012-03-08 2017-04-12 思芬构技术有限公司 用于预测雌性对象中患上癌症的风险或诊断癌症的方法
CN103308673B (zh) 2012-03-08 2017-05-31 思芬构技术有限公司 用于预测雌性对象中发生心血管事件的风险的方法
EP3646880A1 (en) 2012-05-07 2020-05-06 Allergan, Inc. Method of treating amd in patients refractory to anti-vegf therapy
SG11201408196RA (en) * 2012-06-28 2015-03-30 Molecular Partners Ag Designed ankyrin repeat proteins binding to platelet-derived growth factor
AU2012101678B4 (en) * 2012-07-03 2013-01-24 Novartis Ag Use of device
JOP20200175A1 (ar) 2012-07-03 2017-06-16 Novartis Ag حقنة
AU2013100070B4 (en) * 2012-07-03 2013-04-04 Novartis Ag Use of device
JP2015528454A (ja) * 2012-08-28 2015-09-28 ノバルティス アーゲー 眼血管増殖性疾患の処置におけるvegfアンタゴニストの使用
EP2904403B1 (en) 2012-10-02 2018-03-28 SphingoTec GmbH A method for diagnosing or monitoring kidney function or diagnosing kidney dysfunction
EP2738180A1 (en) 2012-11-30 2014-06-04 Molecular Partners AG Binding proteins comprising at least two binding domains against HER2.
CN107991501A (zh) 2013-01-08 2018-05-04 斯弗因高泰克有限公司 生长激素的禁食水平作为心血管风险的预测标志物
EP2961773B1 (en) * 2013-02-26 2019-03-20 Roche Glycart AG Bispecific t cell activating antigen binding molecules
BR112015021000A2 (pt) * 2013-03-14 2017-07-18 Allergan Inc composição de uma distribuição liberação prolongada e método de estabilizar proteínas durante o processo de fabricação
RU2673455C2 (ru) 2013-03-20 2018-11-27 Сфинготек Гмбх Адреномедуллин для направленной терапии по снижению кровяного давления
FR3004650B1 (fr) * 2013-04-22 2015-05-29 Affilogic Composition topique comprenant un variant d'une protéine sauvage à pli-OB, ainsi que son procédé de préparation
JP6486908B2 (ja) 2013-05-31 2019-03-20 モレキュラー パートナーズ アクチェンゲゼルシャフト 肝細胞増殖因子に結合する設計アンキリン反復タンパク質
WO2014203181A1 (en) 2013-06-20 2014-12-24 Novartis Ag Treatment of polypoidal choroidal vasculopathy
EP3010526A1 (en) 2013-06-20 2016-04-27 Novartis AG Use of a vegf antagonist in treating macular edema
US20160137717A1 (en) 2013-06-20 2016-05-19 Gabriela Burian Use of a vegf antagonist in treating choroidal neovascularisation
AU2014288847A1 (en) * 2013-07-11 2016-01-28 Novartis Ag Use of a VEGF antagonist in treating retinopathy of prematurity
MX2016000384A (es) 2013-07-11 2016-04-29 Novartis Ag Uso de un antagonista de vegf en el tratamiento de trastornos coriorretinianos neovasculares y de permeabilidad en pacientes pediatricos.
SG10201912985RA (en) 2013-07-12 2020-02-27 Ophthotech Corp Methods for treating or preventing ophthalmological conditions
KR20160070164A (ko) * 2013-11-05 2016-06-17 알러간, 인코포레이티드 항-vegf darpin으로 눈의 병태를 치료하는 방법
CA2947456C (en) 2014-05-12 2023-03-14 Formycon Ag Pre-filled plastic syringe containing a vegf antagonist
US20160097781A1 (en) 2014-10-01 2016-04-07 Sphingotec Gmbh Method for stratifying a female subject for hormone replacement therapy
EP3277711B9 (en) * 2015-04-02 2023-08-16 Molecular Partners AG Designed ankyrin repeat domains with binding specificity for serum albumin
RU2733471C2 (ru) 2015-04-24 2020-10-01 Сфинготек Гмбх Способ прогнозирования риска развития хронического заболевания почек
TWI799366B (zh) 2015-09-15 2023-04-21 美商建南德克公司 胱胺酸結骨架平臺
BR112018009951A8 (pt) 2015-11-18 2019-02-26 Sio2 Medical Products Inc fármaco oftálmico
BR112018010005A2 (pt) 2015-11-18 2018-11-21 Formycon Ag seringa pré-carregada, e, kit
RU2734958C2 (ru) 2015-11-18 2020-10-26 Формикон Аг Предварительно заполненная фармацевтическая упаковка, содержащая жидкий состав на основе антагониста vegf
EP3407868A1 (en) 2016-01-26 2018-12-05 Formycon AG Liquid formulation of a vegf antagonist
WO2017148904A1 (en) 2016-02-29 2017-09-08 Franz Grus Predictive markers useful in the treatment of wet age-related macular degeneration
CH713803B1 (de) 2016-04-21 2023-08-15 4TEEN4 Pharmaceuticals GmbH Verfahren zur Diagnose durch Bestimmung von DPP3, Hemmer der Aktivität von DPP3 und Zusammensetzung mit einem Hemmer.
MA45493A (fr) 2016-06-27 2019-05-01 Aicuris Anti Infective Cures Gmbh Inhibiteurs d'entrée de hcmv.
WO2018007588A1 (en) 2016-07-08 2018-01-11 Sphingotec Gmbh Adrenomedullin for assessing congestion in a subject with acute heart failure
SG10201912556VA (en) 2016-07-20 2020-02-27 Aerpio Therapeutics Inc HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-ß)
NZ751689A (en) 2016-09-22 2021-07-30 Molecular Partners Ag Recombinant binding proteins and their use
EP3309550A1 (en) 2016-10-12 2018-04-18 sphingotec GmbH Method for the detection of apolipoprotein e4
EP3339324A1 (en) 2016-12-22 2018-06-27 sphingotec GmbH Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in intervention and therapy of congestion in a patient in need thereof
CN110167962B (zh) 2016-12-16 2024-06-07 艾德里诺医药公司 用于干预和治疗需要的患者的充血的抗肾上腺髓质素(ADM)抗体或抗ADM抗体片段或抗ADM非Ig支架
WO2018217995A1 (en) 2017-05-24 2018-11-29 Formycon Ag Sterilizable pre-filled pharmaceutical packages comprising a liquid formulation of a vegf-antagonist
WO2018215580A1 (en) 2017-05-24 2018-11-29 Formycon Ag Method for sterilizing prefilled plastic syringes containing a vegf antagonist
CA3063995A1 (en) 2017-05-24 2018-11-29 Sio2 Medical Products, Inc. Sterilizable pharmaceutical package for ophthalmic formulations
BR112019024966A2 (pt) 2017-05-30 2020-06-23 Sphingotec Gmbh Método para diagnosticar ou monitorar a função renal ou diagnosticar a disfunção renal
TW201904610A (zh) 2017-06-14 2019-02-01 德商拜耳製藥公司 用於治療新生血管型青光眼之非抗體vegf拮抗劑
WO2019020777A1 (en) 2017-07-26 2019-01-31 Formycon Ag LIQUID FORMULATION OF A VEGF ANTAGONIST
EP3668976A1 (en) * 2017-08-18 2020-06-24 Cambridge Enterprise Limited Modular binding proteins
EP4159229A1 (en) 2017-09-25 2023-04-05 AdrenoMed AG Anti-adrenomedullin (adm) binder for use in therapy or prevention of symptoms of illness
BR112020005682A2 (pt) 2017-10-18 2020-10-20 Adrenomed Ag monitoração de terapia sob tratamento com um aglutinante de antiadrenomedulina (adm)
CN111542755A (zh) 2017-10-24 2020-08-14 思芬构技术有限公司 用于预测第一次心血管事件的硒蛋白p
US11530276B2 (en) 2017-10-25 2022-12-20 4TEEN4 Pharmaceuticals GmbH DPP3 binder directed to and binding to specific DPP3-epitopes and its use in the prevention or treatment of diseases / acute conditions that are associated with oxidative stress
BR112020014940A2 (pt) 2018-02-08 2020-12-08 Sphingotec Gmbh Adrenomedulina (adm) para diagnóstico e/ou predição de demência e ligante antiadrenomedulina para uso em terapia e prevenção de demência
EP3569614A1 (en) 2018-05-18 2019-11-20 Julius-Maximilians-Universität Würzburg Compounds and methods for the immobilization of myostatin-inhibitors on the extracellular matrix by transglutaminase
EP3586865A1 (en) 2018-06-21 2020-01-01 Charité - Universitätsmedizin Berlin Complement anaphylatoxin binders and their use in treatment of a subject having an ocular wound and/or fibrosis
WO2020068653A1 (en) 2018-09-24 2020-04-02 Aerpio Pharmaceuticals, Inc. MULTISPECIFIC ANTIBODIES THAT TARGET HPTP - β (VE-PTP) AND VEGF
BR112021010069A2 (pt) 2018-12-20 2021-11-23 Sphingotec Gmbh Selenoproteína p em insuficiência cardíaca
CN113557031A (zh) 2018-12-21 2021-10-26 4Teen4制药有限公司 使用血管紧张肽受体激动剂和/或其前体的治疗的疗法指导和/或疗法监测
AU2020289080A1 (en) 2019-06-04 2021-12-23 Molecular Partners Ag Multispecific proteins
CN114364984A (zh) 2019-08-15 2022-04-15 思芬构技术有限公司 一种诊断或监测儿科患者的肾功能或诊断肾功能障碍的方法
US20220307065A1 (en) 2019-08-30 2022-09-29 4TEEN4 Pharmaceuticals GmbH Therapy guidance and/or therapy monitoring for treatment of shock
CN115003689A (zh) 2019-12-11 2022-09-02 分子合作伙伴股份公司 具有改变的表面残基的经设计的锚蛋白重复结构域
EP3871689A1 (en) 2020-02-26 2021-09-01 sphingotec GmbH Anti-adm-antibodies binding to the free n-terminus for accelerated transition of adm-gly to bio-adm in patients with adm-gly/ bio-adm ratio above a threshold and combination with vitamin c
KR20220145897A (ko) 2020-02-27 2022-10-31 아드레노메드 아게 쇼크의 치료 또는 예방에 사용하기 위한 항-아드레노메둘린 (adm) 항체 또는 항-adm 항체 단편 또는 항-adm 비-ig 스캐폴드
CN115244401A (zh) 2020-02-27 2022-10-25 4Teen4制药有限公司 用于在休克患者中进行nt-adm抗体的治疗指导、监测和分层的dpp3
KR20220145898A (ko) 2020-02-27 2022-10-31 아드레노메드 아게 쇼크 환자의 치료에 사용하기 위한 항-아드레노메둘린 (adm) 결합제
EP3922993A1 (en) 2020-06-12 2021-12-15 4TEEN4 Pharmaceuticals GmbH Dpp3 in patients infected with coronavirus
BR112022017277A2 (pt) 2020-03-16 2022-10-18 4TEEN4 Pharmaceuticals GmbH Dpp3 em pacientes infectados com coronavírus
AU2021238592A1 (en) 2020-03-16 2022-11-03 Sphingotec Gmbh Pro-Adrenomedullin or fragment thereof in patients infected with Corona virus and treatments with binder against Adrenomedullin
CR20220618A (es) 2020-05-06 2023-01-19 Molecular Partners Ag Nuevas proteinas de unión a repeticiones de anquirina y sus usos
JP2023528204A (ja) 2020-05-14 2023-07-04 モレキュラー パートナーズ アクチェンゲゼルシャフト 多選択性タンパク質
EP4023218A1 (en) 2020-12-02 2022-07-06 S-Form Pharma Combination therapy for patients having acute and/or persistent dyspnea
AU2021403833A1 (en) 2020-12-16 2023-07-27 Molecular Partners Ag Novel slow-release prodrugs
BR112023018293A2 (pt) 2021-03-09 2023-10-31 Molecular Partners Ag Acopladores de célula t multiespecíficos à base de darpin
JP2024509241A (ja) 2021-03-09 2024-02-29 モレキュラー パートナーズ アクチェンゲゼルシャフト 新規のDARPinに基づくCD123エンゲージャ
AU2022231913A1 (en) 2021-03-09 2023-09-28 Molecular Partners Ag Novel darpin based cd33 engagers
EP4305063A1 (en) 2021-03-09 2024-01-17 Molecular Partners AG Protease cleavable prodrugs
WO2022263648A1 (en) 2021-06-18 2022-12-22 Sphingotec Gmbh A method for predicting sepsis and septic shock
KR20240041912A (ko) 2021-06-29 2024-04-01 베리솔 게엠베하 체액내 셀레늄 결핍을 식별하기 위한 복합 바이오마커
EP4145456A1 (en) 2021-09-06 2023-03-08 Bayer AG Prediction of a change related to a macular fluid
CA3239407A1 (en) 2021-12-14 2023-06-22 Simon FONTAINE Designed repeat domains with dual binding specificity and their use
WO2023175035A1 (en) 2022-03-15 2023-09-21 Adrenomed Ag Stable aqueous formulation of an anti-adrenomedullin (adm) antibody or anti-adm antibody fragment
WO2024023369A1 (en) 2022-07-29 2024-02-01 Adrenomed Ag Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy or prevention of shock
WO2024023368A1 (en) 2022-07-29 2024-02-01 4TEEN4 Pharmaceuticals GmbH Prediction of an increase of dpp3 in a patient with septic shock
US20240132546A1 (en) 2022-07-31 2024-04-25 Molecular Partners Ag Charge modified designed repeat domains and their use
WO2024038307A1 (en) 2022-08-19 2024-02-22 Novartis Ag Dosing regimens for sars-cov-2 binding molecules
WO2024059686A2 (en) * 2022-09-15 2024-03-21 The Regents Of The University Of California Darpin backbones and rigidified electron microscopy imaging scaffolds

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE68927933T2 (de) 1988-09-02 1997-08-14 Dyax Corp Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
US5348867A (en) 1991-11-15 1994-09-20 George Georgiou Expression of proteins on bacterial surface
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
CA2196496A1 (en) 1997-01-31 1998-07-31 Stephen William Watson Michnick Protein fragment complementation assay for the detection of protein-protein interactions
DE69841815D1 (de) 1997-04-07 2010-09-16 Genentech Inc Anti-VEGF Antikörper
SI1325932T1 (pt) 1997-04-07 2005-08-31 Genentech Inc
WO1998048008A1 (en) 1997-04-23 1998-10-29 Plueckthun Andreas Methods for identifying nucleic acid molecules encoding (poly)peptides that interact with target molecules
WO2000032823A1 (en) 1998-12-02 2000-06-08 Phylos, Inc. Dna-protein fusions and uses thereof
US7087411B2 (en) * 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
CA2376379C (en) 1999-06-08 2007-08-07 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
WO2002020565A2 (en) 2000-09-08 2002-03-14 Universität Zürich Collections of repeat proteins comprising repeat modules
RU2299208C2 (ru) * 2001-05-08 2007-05-20 Шеринг Акциенгезельшафт Антраниламидпиридинамиды избирательного действия в качестве ингибиторов vegfr-2 и vegfr-3
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
US7772188B2 (en) * 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
EP1711196A4 (en) * 2003-12-05 2011-09-14 Bristol Myers Squibb Co INHIBITORS OF TYPE-2 VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTORS
EA013615B1 (ru) * 2004-11-12 2010-06-30 Байер Шеринг Фарма Акциенгезельшафт Рекомбинантный онколитический парамиксовирус и его применение
CA2995971A1 (en) * 2005-03-25 2006-10-05 Regeneron Pharmaceuticals, Inc. Vegf antagonist formulations
RU2412249C2 (ru) 2005-07-08 2011-02-20 Юниверсити Оф Цюрих Фаговый дисплей с применением котрансляционной транслокации слитых полипептидов
EP2727936B1 (en) * 2006-11-22 2016-09-07 Bristol-Myers Squibb Company Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including IGF-IR
JP2010518013A (ja) * 2007-02-01 2010-05-27 ジェネンテック, インコーポレイテッド 血管形成阻害剤を含む組み合わせ治療の方法
US20100144599A1 (en) 2007-02-02 2010-06-10 Bristol-Myers Squibb Company Vegf pathway blockade

Also Published As

Publication number Publication date
CN102272148A (zh) 2011-12-07
JP2015133978A (ja) 2015-07-27
IL212589A0 (en) 2011-07-31
US20150344539A1 (en) 2015-12-03
US8901076B2 (en) 2014-12-02
BRPI0921469B1 (pt) 2022-01-18
NZ592591A (en) 2012-04-27
MX359570B (es) 2018-10-01
JP5954990B2 (ja) 2016-07-20
CN107011425A (zh) 2017-08-04
KR101698362B1 (ko) 2017-01-20
CN107011425B (zh) 2021-01-01
CA2742241A1 (en) 2010-06-03
US20110207668A1 (en) 2011-08-25
ES2836948T3 (es) 2021-06-28
RU2650765C1 (ru) 2018-04-17
EP2358746B1 (en) 2020-09-16
JP6329503B2 (ja) 2018-05-23
AU2009319204B2 (en) 2014-11-13
DK2358746T3 (da) 2020-12-21
AU2009319204A1 (en) 2010-06-03
RU2550258C2 (ru) 2015-05-10
EP3785735A1 (en) 2021-03-03
JP2012507271A (ja) 2012-03-29
EP2358746A1 (en) 2011-08-24
WO2010060748A1 (en) 2010-06-03
MX2011004649A (es) 2011-05-30
KR20110082528A (ko) 2011-07-19
IL212589A (en) 2017-01-31
RU2011122201A (ru) 2012-12-10
CA2742241C (en) 2019-12-10

Similar Documents

Publication Publication Date Title
BRPI0921469A2 (pt) proteínas de ligação que inibem a interação com o receptor de vegf-a
CY2019004I1 (el) Τροποποιημενα αντισωματα αντι-ιl-23ρ19
BRPI0922505A2 (pt) proteínas de ligação a receptor cgrp humano
IS8842A (is) Kjarnviðtaka bindimiðlar.
IL222749A0 (en) Modified binding proteins inhibiting the vegf-a receptor interaction
NO20072812L (no) Forbedret oreenhet
ATE509022T1 (de) Nikotin-acetylcholin-rezeptorsubtyp-selektive diazabicycloalkanamide
BRPI0720699A2 (pt) Programas ligados
NO20074696L (no) Aktiveringsmekanisme
BRPI0910835A2 (pt) conjunto com pílulas hemostáticas e radiograficamente detectáveis
DE602008004276D1 (de) Luftkanone
BRPI0913515A2 (pt) fechamento com mecanismo limitador
BRPI0919024A2 (pt) compostos que seletivamente modulam o receptor cb2
SE0850135L (sv) Häftapparat
BRPI0909289A2 (pt) Mistura simbiótica
BRPI0913513A2 (pt) fechamento com mecanismo limitador
ATE539819T1 (de) Elektronisch gesteuertes zapfenbelastungssystem
BRPI0812991A2 (pt) Utilização de combustível melhorado
DK2126380T3 (da) Rillet befæstigelseselement
DE602008005825D1 (de) Luftdruckwaffe
BRPI0914557A2 (pt) proteína de ligação de biotina modificada
FI20080585A (fi) Telkimekanismi
DE602007008589D1 (de) Pyridooxazepin-progesteronrezeptor-modulatoren
BRPI0817449A2 (pt) Composição de combustível
DE112008001259A5 (de) Dosiermagnet

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 03/11/2009, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.